BR9910725A - Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14 - Google Patents

Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14

Info

Publication number
BR9910725A
BR9910725A BR9910725-2A BR9910725A BR9910725A BR 9910725 A BR9910725 A BR 9910725A BR 9910725 A BR9910725 A BR 9910725A BR 9910725 A BR9910725 A BR 9910725A
Authority
BR
Brazil
Prior art keywords
leu
proteins
lait
peptides
induction
Prior art date
Application number
BR9910725-2A
Other languages
English (en)
Inventor
Michael H Julius
Dominik Filipp
Original Assignee
Gemma Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemma Biotechnology Ltd filed Critical Gemma Biotechnology Ltd
Publication of BR9910725A publication Critical patent/BR9910725A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

<B>INDUçãO DE PROTEìNAS E PEPTìDEOS ANTIBIóTICOS POR PROTEìNA LAIT/s CD14<D> Processo para melhorar os sintomas de septicemia compreendendo exposição direta das células epiteliais de um mamífero que precise à CD14 solúvel ou variantes ativas da mesma. é descrito um processo para obter CD14 de uma solução de estoque contendo proteína de uma secreção mamária. é descrito o processo para ativar diretamente as células B usando um polipeptídeo solúvel possuindo uma seq³ência de aminoácidos selecionada do grupo que compreende leu-leu-leu-leu-leu-leu-pro-ser, leu-leu-leu-leu-leu-leu-pro-leu e leu-leu leu-leu-leu-leu-val-his e que é especificamente reconhecida pelo anticorpo monoclonal 3C10 e que ativa células B. é descrito DNA genómico CD14 bovino.
BR9910725-2A 1998-05-27 1999-05-27 Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14 BR9910725A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8688498P 1998-05-27 1998-05-27
PCT/CA1999/000482 WO1999061468A2 (en) 1998-05-27 1999-05-27 The induction of antibiotic peptides by lait (scd14) protein

Publications (1)

Publication Number Publication Date
BR9910725A true BR9910725A (pt) 2001-01-30

Family

ID=22201526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910725-2A BR9910725A (pt) 1998-05-27 1999-05-27 Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14

Country Status (14)

Country Link
US (1) US7592310B2 (pt)
EP (1) EP1080111B1 (pt)
JP (1) JP2002516339A (pt)
CN (1) CN1322214A (pt)
AU (1) AU771448B2 (pt)
BR (1) BR9910725A (pt)
CA (1) CA2328134A1 (pt)
CZ (1) CZ20004256A3 (pt)
HK (1) HK1041892A1 (pt)
HU (1) HUP0101987A3 (pt)
ID (1) ID26730A (pt)
IL (1) IL139339A0 (pt)
PL (1) PL345208A1 (pt)
WO (1) WO1999061468A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347069A1 (en) * 1998-10-20 2000-04-27 Societe Des Produits Nestle S.A. Protein for treatment or prevention of a gastrointestinal tract disorder
WO2001072993A1 (fr) * 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Inhibiteur de liaison entre le recepteur de type toll et cd14
WO2004103294A2 (en) 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
ES2406266T3 (es) * 2004-05-11 2013-06-06 Mochida Pharmaceutical Co., Ltd. Antígeno CD14 soluble novedoso
US20100331239A1 (en) * 2008-01-29 2010-12-30 The Medical Research, Infrastructure And Health Services Cd14 and peptides thereof for protection of cells against cell death
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY &amp; FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
ES2684696T3 (es) 2009-04-27 2018-10-04 Immuron Limited Preparación de inmunoglobulina enriquecida con anti-LPS para su uso en el tratamiento y/o la profilaxis de esteatohepatitis no alcohólica
US9943597B2 (en) 2010-08-17 2018-04-17 Immuron Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
KR101935071B1 (ko) * 2011-05-19 2019-01-03 모찌다 세이야쿠 가부시끼가이샤 혈액 검체를 사용한 호흡기 감염증의 진단

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543303A (en) * 1988-11-28 1996-08-06 Goyert; Sanna M. Recombinant myelomonocytic differentiation antigen CD14
DE69032662T2 (de) * 1989-08-01 1999-03-11 Rockefeller University, New York, N.Y. Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5714469A (en) * 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
WO1996020957A1 (en) * 1994-12-30 1996-07-11 Amgen Inc. Anti-inflammatory cd14 polypeptides
AU5688596A (en) 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
PL185442B1 (pl) 1996-10-03 2003-05-30 Georgiades Biotech Ltd Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
PL345208A1 (en) 2001-12-03
HUP0101987A2 (hu) 2001-09-28
HK1041892A1 (zh) 2002-07-26
EP1080111B1 (en) 2012-07-25
AU4025899A (en) 1999-12-13
CA2328134A1 (en) 1999-12-02
ID26730A (id) 2001-02-01
US20040259795A1 (en) 2004-12-23
WO1999061468A3 (en) 2000-04-06
US7592310B2 (en) 2009-09-22
JP2002516339A (ja) 2002-06-04
CZ20004256A3 (cs) 2001-09-12
WO1999061468A2 (en) 1999-12-02
IL139339A0 (en) 2001-11-25
EP1080111A2 (en) 2001-03-07
AU771448B2 (en) 2004-03-25
CN1322214A (zh) 2001-11-14
HUP0101987A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
Chung et al. Properties of a basement membrane-related glycoprotein synthesized in culture by a mouse embryonal carcinoma-derived cell line
Schopperle et al. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin
TAYLOR et al. Immunofluorescent localization of vitamin D-dependent calcium-binding protein
BR9712298A (pt) Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
Obinata et al. Immunochemical analysis of C-protein isoform transitions during the development of chicken skeletal muscle
BR9809443A (pt) Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
Moll et al. Variability of expression and arrangement of cytokeratin and neurofilaments in cutaneous neuroendocrine carcinomas (Merkel cell tumors): immunocytochemical and biochemical analysis of twelve cases
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
BR9908083A (pt) polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção de m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpo monoclonal, e, proteìna de fusão
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
BR0015137A (pt) Peptìdeos antigênicos de neisseria
BR9702179A (pt) Conjugado processo para tratamento de uma doença em um mamífero e composição farmacêutica
KR910002897A (ko) 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체
Gibbs et al. Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variation in the cellular location in different tissues.
BR9808545A (pt) ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
Godkin et al. Characterization of bovine conceptus proteins produced during the peri-and postattachment periods of early pregnancy
Unsworth et al. Studies on reticulin. I: Serological and immunohistological investigations of the occurrence of collagen type III, fibronectin and the non-collagenous glycoprotein of Pras and Glynn in reticulin.
Conrad et al. Biochemical identification and tissue-specific expression patterns of keratins in the zebrafish Danio rerio
BR9910725A (pt) Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14
Fulcher et al. Endopeptidase-24.11 purified from pig intestine is differently glycosylated from that in kidney
ES2173471T3 (es) Analisis para homocisteina y homocisteina desulfurasa a partir de tricomonas viginalis de protozoos.
Settleman et al. Chromogranin, an integral membrane protein.
Zhang et al. Correlation of epididymal protease inhibitor and fibronectin in human semen
Allen et al. Localization of endogenous β-galactoside-binding lectin in human cells and tissues
BRPI0406265B8 (pt) método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/705 (2006.01), A61K 38/00 (2006.0